ESMO 2024 GU Update

ESMO 2024 GU Update

Up next

Transitioning from Fellow to Attending with Dr. Laura Vater

This week’s episode we have a very special guest, friend and colleague Dr. Laura Vater joining us to talk about one of the biggest transitions in medicine—moving from fellow to attending.Dr Vater is a GI oncologist at IU, writer, and speaker. She focuses on the dignity of patient ...  Show more

ASCO 2026 Plenary: SARC-041

This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progres ...  Show more

Recommended Episodes

Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer
The Uromigos

Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer

 

Kidney cancer - Take home messages for 2024
EAU Podcasts

The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk and Dr. Riccardo Bertolo share highlights of the important kidney cancer developments for 2024. 

They summarise the results on several important trials such as FASTRACK, ...

  Show more

Ep. 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder and Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas
BackTable Urology

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

What's New in Prostate Cancer, RCC, and mUC at GU24
ASCO Daily News

Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ...

  Show more